Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021
During January–August 2021, the Community Prevalence of SARS-CoV-2 Study used time/location sampling to recruit a cross-sectional, population-based cohort to estimate SARS-CoV-2 seroprevalence and nasal swab sample PCR positivity across 15 US communities. Survey-weighted estimates of SARS-CoV-2 infection and vaccine willingness among participants at each site were compared within demographic groups by using linear regression models with inverse variance weighting. Among 22,284 persons <2 months of age and older, median prevalence of infection (prior, active, or both) was 12.9% across sites and similar across age groups. Within each site, average prevalence of infection was 3 percentage points higher for Black than White persons and average vaccine willingness was 10 percentage points lower for Black than White persons and 7 percentage points lower for Black persons than for persons in other racial groups. The higher prevalence of SARS-CoV-2 infection among groups with lower vaccine willingness highlights the disparate effect of COVID-19 and its complications..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Emerging Infectious Diseases - 30(2024), 2, Seite 245-254 |
| Sprache: |
Englisch |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
2019 novel coronavirus disease |
|---|
| doi: |
10.3201/eid3002.230863 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ096503270 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096503270 | ||
| 003 | DE-627 | ||
| 005 | 20240413152144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid3002.230863 |2 doi | |
| 035 | |a (DE-627)DOAJ096503270 | ||
| 035 | |a (DE-599)DOAJ05b524e875824a568c8cba93369effc1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Jessica Justman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a During January–August 2021, the Community Prevalence of SARS-CoV-2 Study used time/location sampling to recruit a cross-sectional, population-based cohort to estimate SARS-CoV-2 seroprevalence and nasal swab sample PCR positivity across 15 US communities. Survey-weighted estimates of SARS-CoV-2 infection and vaccine willingness among participants at each site were compared within demographic groups by using linear regression models with inverse variance weighting. Among 22,284 persons <2 months of age and older, median prevalence of infection (prior, active, or both) was 12.9% across sites and similar across age groups. Within each site, average prevalence of infection was 3 percentage points higher for Black than White persons and average vaccine willingness was 10 percentage points lower for Black than White persons and 7 percentage points lower for Black persons than for persons in other racial groups. The higher prevalence of SARS-CoV-2 infection among groups with lower vaccine willingness highlights the disparate effect of COVID-19 and its complications. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a 2019 novel coronavirus disease | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a viruses | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Timothy Skalland |e verfasserin |4 aut | |
| 700 | 0 | |a Ayana Moore |e verfasserin |4 aut | |
| 700 | 0 | |a Christopher I. Amos |e verfasserin |4 aut | |
| 700 | 0 | |a Mark A. Marzinke |e verfasserin |4 aut | |
| 700 | 0 | |a Sahar Z. Zangeneh |e verfasserin |4 aut | |
| 700 | 0 | |a Colleen F. Kelley |e verfasserin |4 aut | |
| 700 | 0 | |a Rebecca Singer |e verfasserin |4 aut | |
| 700 | 0 | |a Stockton Mayer |e verfasserin |4 aut | |
| 700 | 0 | |a Yael Hirsch-Moverman |e verfasserin |4 aut | |
| 700 | 0 | |a Susanne Doblecki-Lewis |e verfasserin |4 aut | |
| 700 | 0 | |a David Metzger |e verfasserin |4 aut | |
| 700 | 0 | |a Elizabeth Barranco |e verfasserin |4 aut | |
| 700 | 0 | |a Ken Ho |e verfasserin |4 aut | |
| 700 | 0 | |a Ernesto T.A. Marques |e verfasserin |4 aut | |
| 700 | 0 | |a Margaret Powers-Fletcher |e verfasserin |4 aut | |
| 700 | 0 | |a Patricia J. Kissinger |e verfasserin |4 aut | |
| 700 | 0 | |a Jason E. Farley |e verfasserin |4 aut | |
| 700 | 0 | |a Carrie Knowlton |e verfasserin |4 aut | |
| 700 | 0 | |a Magdalena E. Sobieszczyk |e verfasserin |4 aut | |
| 700 | 0 | |a Shobha Swaminathan |e verfasserin |4 aut | |
| 700 | 0 | |a Domonique Reed |e verfasserin |4 aut | |
| 700 | 0 | |a Jean De Dieu Tapsoba |e verfasserin |4 aut | |
| 700 | 0 | |a Lynda Emel |e verfasserin |4 aut | |
| 700 | 0 | |a Ian Bell |e verfasserin |4 aut | |
| 700 | 0 | |a Krista Yuhas |e verfasserin |4 aut | |
| 700 | 0 | |a Leah Schrumpf |e verfasserin |4 aut | |
| 700 | 0 | |a Laura Mkumba |e verfasserin |4 aut | |
| 700 | 0 | |a Jontraye Davis |e verfasserin |4 aut | |
| 700 | 0 | |a Jonathan Lucas |e verfasserin |4 aut | |
| 700 | 0 | |a Estelle Piwowar-Manning |e verfasserin |4 aut | |
| 700 | 0 | |a Shahnaz Ahmed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Emerging Infectious Diseases |d Centers for Disease Control and Prevention, 2003 |g 30(2024), 2, Seite 245-254 |w (DE-627)DOAJ000014966 |x 10806059 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g pages:245-254 |
| 856 | 4 | 0 | |u https://doi.org/10.3201/eid3002.230863 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/05b524e875824a568c8cba93369effc1 |z kostenfrei |
| 856 | 4 | 0 | |u https://wwwnc.cdc.gov/eid/article/30/2/23-0863_article |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6040 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6059 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |h 245-254 | ||